Results 31 to 40 of about 121,912 (288)

Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management

Cancer Communications, Volume 42, Issue 12, Page 1257-1287, December 2022., 2022
Abstract Clustered regularly interspaced short palindromic repeats‐associated protein (CRISPR/Cas9), an adaptive microbial immune system, has been exploited as a robust, accurate, efficient and programmable method for genome targeting and editing. This innovative and revolutionary technique can play a significant role in animal modeling, in vivo genome
Khaled S. Allemailem, Mohammed A Alsahli, Ahmad Almatroudi, Faris Alrumaihi, Fahd Khaleefah Alkhaleefah, Arshad Husain Rahmani, Amjad Ali Khan   +6 more
wiley   +1 more source

Dual-path convolutional neural network using micro-FTIR imaging to predict breast cancer subtypes and biomarkers levels: estrogen receptor, progesterone receptor, HER2 and Ki67 [PDF]

arXiv, 2023
Breast cancer molecular subtypes classification plays an import role to sort patients with divergent prognosis. The biomarkers used are Estrogen Receptor (ER), Progesterone Receptor (PR), HER2, and Ki67. Based on these biomarkers expression levels, subtypes are classified as Luminal A (LA), Luminal B (LB), HER2 subtype, and Triple-Negative Breast ...
arxiv  

Molecular and cellular paradigms of multidrug resistance in cancer

Cancer Reports, Volume 5, Issue 12, December 2022., 2022
Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya, Abu Sufiyan Chhipa, Vinita Mishra, Vishal Kumar Gupta, Shiv Govind Rawat, Ajay Kumar, Chandramani Pathak   +6 more
wiley   +1 more source

Expression of estrogen and progesterone receptors in astrocytomas: a literature review

Clinics
Gliomas are the most common type of primary central nervous system neoplasm. Astrocytomas are the most prevalent type of glioma and these tumors may be influenced by sex steroid hormones.
Cléciton Braga Tavares, Francisca das Chagas Sheyla Almeida Gomes-Braga, Danylo Rafhael Costa-Silva, Carla Solange Escórcio-Dourado, Umbelina Soares Borges, Airton Mendes Conde-Junior, Maria da Conceição Barros-Oliveira, Emerson Brandão Sousa, Lorena da Rocha Barros, Luana Mota Martins, Gil Facina, Benedito Borges da-Silva   +11 more
doaj   +1 more source

BMPR2 expression is suppressed by signaling through the estrogen receptor

Biology of Sex Differences, 2012
Background Studies in multiple organ systems have shown cross-talk between signaling through the bone morphogenetic protein receptor type 2 (BMPR2) and estrogen pathways.
Austin Eric D, Hamid Rizwan, Hemnes Anna R, Loyd James E, Blackwell Tom, Yu Chang, Phillips III John A, Gaddipati Radhika, Gladson Santhi, Gu Everett, West James, Lane Kirk B   +11 more
doaj   +1 more source

FMO Interaction Energy between 17$β$-Estradiol, 17$α$-Estradiol and Human Estrogen Receptor $α$ [PDF]

arXiv, 2020
The estrogen receptor is a nuclear hormone receptor activated by the natural steroid hormone 17$\beta$-estradiol (E2). Fragment molecular orbital (FMO) calculations were performed which allowed us to obtain the interaction energy ($E_{int}$) between E2, 17$\alpha$-estradiol (17$\alpha$-E2) and the human estrogen receptor $\alpha$ ligand-binding domain.
arxiv  

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Maternal obesity and resistance to breast cancer treatments among offspring: Link to gut dysbiosis

Cancer Reports, Volume 5, Issue 12, December 2022., 2022
Abstract Background About 50 000 new cases of cancer in the United States are attributed to obesity. The adverse effects of obesity on breast cancer may be most profound when affecting the early development; that is, in the womb of a pregnant obese mother.
Fabia de Oliveira Andrade, Vivek Verma, Leena Hilakivi‐Clarke   +2 more
wiley   +1 more source

17β-Hydroxysteroid dehydrogenase type I and aromatase in ovarian cortical inclusion cysts

Endocrine Connections
Previous evidence suggests a link between the ovarian surface epithelium and cortical inclusion cysts and the origin of epithelial ovarian cancer.
Enrique Pedernera, Flavia Morales-Vásquez, Delia Pérez-Montiel, Elizabeth Rendon, Esteban Mena, Laura Diaz-Cueto, Carmen Mendez   +6 more
doaj   +1 more source

Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. [PDF]

PLoS ONE, 2008
BackgroundEstrogen is an established enhancer of breast cancer development, but less is known on its effect on local progression or metastasis. We studied the effect of estrogen receptor recruitment on actin cytoskeleton remodeling and breast cancer cell
Maria Silvia Giretti, Xiao-Dong Fu, Giovanni De Rosa, Ivana Sarotto, Chiara Baldacci, Silvia Garibaldi, Paolo Mannella, Nicoletta Biglia, Piero Sismondi, Andrea Riccardo Genazzani, Tommaso Simoncini   +10 more
doaj   +1 more source